Evicenter
MarkdownMedical informationP&T meetings
Obefazimod (ABX464)

Ulcerative colitis

Manufacturer
Abivax
Launch
Not announced
Last updated
173 sources

Clinical evidence

ABTECT maintenance

75 evidence topics · 13 sources

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using clinical remission by modified mayo score as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Part 1 analysis population: 580 obefazimod induction responders
GroupParticipants
Obefazimod induction responders“Obefazimod Induction Responders (n=580)”
Placebo“Placebo (n=192)”
Obefazimod 25 mg“25 mg (n=193)”
Obefazimod 50 mg“50 mg (n=195)”
Part 2 induction non-responders and Part 1 relapsers analyzed for efficacy
GroupParticipants
Induction non-responders, obefazimod 25 mg“(N=81)”
Induction non-responders, obefazimod 50 mg“(N=148)”
Part 1 relapsers, placebo then obefazimod 50 mg“(N=109)”
Part 1 relapsers, obefazimod 25 mg then 50 mg“(N=33)”
Description of analysis sets
Results
Participant disposition
Week 44 completion without relapse or treatment switch, by group
MeasurePlaceboObefazimod 25 mgObefazimod 50 mg
Study participants“192”“193”“195”
Week 44 completion rate“66 (34.3%)”“152 (78.8%)”“160 (82.1%)”
Baseline characteristics
Part 1 baseline characteristics by group
CharacteristicPlaceboObefazimod 25 mgObefazimod 50 mg
Study participants“192”“193”“195”
Age (years), mean (SD)“41.3 (13.4)”“43.0 (13.7)”“42.3 (14.4)”
Induction baseline modified Mayo Score, mean (SD)“6.9 (1.1)”“6.7 (1.1)”“6.9 (1.2)”
Duration of disease (years), mean (SD)“8.1 (7.6)”“8.1 (7.4)”“7.8 (6.9)”
Induction baseline fecal calprotectin (mg/g), median“1,202”“1,585”“1,568”
Corticosteroid use at maintenance baseline“35.9%”“41.5%”“40.5%”
Clinical remission at maintenance baseline“27.1%”“37.8%”“32.3%”
Prior advanced therapy failure“37.5%”“39.4%”“46.2%”
Efficacy results
Part 1 primary and key secondary endpoints at Week 44
Endpoint at Week 44Placebo (N=192)Obefazimod 25 mg (N=193)Obefazimod 50 mg (N=195)Difference, 25 mgDifference, 50 mgP value (both doses)
Clinical remission, n (%)“20 (10.4%)”“98 (50.8%)”“100 (51.3%)”“∆39.3%”“∆40.3%”“<0.0001”
Endoscopic improvement, n (%)“24 (12.5%)”“106 (54.9%)”“125 (64.1%)”“∆42.5%”“∆51.0%”“<0.0001”
Endoscopic remission, n (%)“19 (9.9%)”“80 (41.5%)”“93 (47.7%)”“∆31.4%”“∆37.8%”“<0.0001”
HEMI, n (%)“20 (10.4%)”“97 (50.3%)”“112 (57.4%)”“∆39.4%”“∆46.5%”“<0.0001”
Corticosteroid-free clinical remission, n (%)“19 (9.9%)”“87 (45.1%)”“93 (47.7%)”“∆35.1%”“∆38.0%”“<0.0001”
Sustained clinical remission, n/N (%)“8/51 (15.7%)”“49/73 (67.1%)”“40/61 (65.6%)”“∆52.8%”“∆49.1%”“<0.0001”
Clinical endpoints at Week 52 by prior inadequate response to advanced therapy
Subgroup and endpointPlacebo, n/NObefazimod 25 mg, n/NObefazimod 50 mg, n/NDifference, 25 mgP value, 25 mgDifference, 50 mgP value, 50 mg
No prior AT-IR: clinical remission“15/120”“72/117”“62/105”“∆ 48%”“p<0.0001”“∆ 45%”“p<0.0001”
No prior AT-IR: corticosteroid-free clinical remission“15/120”“64/117”“59/105”“∆ 42%”“p<0.0001”“∆ 43%”“p<0.0001”
No prior AT-IR: sustained clinical remission“5/38”“42/58”“27/38”“∆ 62%”“p<0.0001”“∆ 55%”“p=0.0003”
Prior AT-IR: clinical remission“5/72”“26/76”“38/90”“∆ 28%”“p<0.0001”“∆ 33%”“p<0.0001”
Prior AT-IR: corticosteroid-free clinical remission“4/72”“23/76”“34/90”“∆ 26%”“p=0.0001”“∆ 31%”“p<0.0001”
Prior AT-IR: sustained clinical remission“3/13”“7/15”“13/23”“∆ 24%”“p=0.6873”“∆ 30%”“p=0.0915”
Endoscopic and histologic-endoscopic endpoints at Week 52 by prior inadequate response to advanced therapy
Subgroup and endpointPlacebo, n/NObefazimod 25 mg, n/NObefazimod 50 mg, n/N
No prior AT-IR: endoscopic improvement“18/120”“77/117”“77/105”
No prior AT-IR: endoscopic remission“15/120”“62/117”“58/105”
No prior AT-IR: HEMI“15/120”“71/117”“68/105”
Prior AT-IR: endoscopic improvement“6/72”“29/76”“48/90”
Prior AT-IR: endoscopic remission“4/72”“18/76”“35/90”
Prior AT-IR: HEMI“5/72”“26/76”“44/90”
Clinical remission at Week 52 by number of prior advanced therapies with inadequate response and after JAK inhibitor failure
SubgroupPlacebo, n/NObefazimod 25 mg, n/NObefazimod 50 mg, n/NDifference, 25 mgP value, 25 mgDifference, 50 mgP value, 50 mg
No prior AT-IR“15/120”“72/117”“62/105”“∆ 49%”“p<0.0001”“∆ 47%”“p<0.0001”
One prior AT-IR“4/27”“12/31”“17/41”“∆ 24%”“p=0.2785”“∆ 27%”“p=0.0584”
Two prior AT-IR“0/24”“7/22”“8/19”“∆ 32%”“p=0.0215”“∆ 42%”“p=0.0014”
Three prior AT-IR“1/12”“4/12”“10/21”“∆ 25%”“p=0.0771”“∆ 39%”“p=0.0968”
Four or more prior AT-IR“0/9”“3/11”“3/9”“∆ 27%”“NC”“∆ 33%”“p=0.1967”
Prior JAK inhibitor inadequate response“0/16”“4/14”“5/15”“∆ 29%”“p=0.0190”“∆ 33%”“p=0.0375”
Part 2: induction non-responders continuing obefazimod, exploratory endpoints at Week 44
EndpointObefazimod 25 mg (N=81)Obefazimod 50 mg (N=148)
Clinical remission“23.5%”“37.2%”
Clinical response“50.6%”“61.5%”
Endoscopic improvement“28.4%”“48.0%”
HEMI“23.5%”“44.6%”
Endoscopic remission“22.2%”“34.5%”
Part 2: Part 1 relapsers re-treated with obefazimod 50 mg, exploratory endpoints at Week 44
EndpointPlacebo in Part 1, then 50 mg (N=109)Obefazimod 25 mg in Part 1, then 50 mg (N=33)
Clinical remission“45.0%”“45.5%”
Clinical response“69.7%”“66.7%”
Endoscopic improvement“54.1%”“45.5%”
HEMI“47.7%”“39.4%”
Endoscopic remission“32.1%”“24.2%”
Health-related quality of life and patient-reported outcomes
Safety results
Part 1 treatment-emergent adverse events over 44 weeks
Event, n (%)Placebo (N=192)Obefazimod 25 mg (N=193)Obefazimod 50 mg (N=195)
Any TEAE“96 (50.0%)”“112 (58.0%)”“140 (71.8%)”
TEAE leading to study drug discontinuation“13 (6.8%)”“5 (2.6%)”“9 (4.6%)”
Serious TEAE“8 (4.2%)”“5 (2.6%)”“11 (5.6%)”
Death“0”“0”“0”
Serious or severe (grade 3 or higher) infections and opportunistic infections“2 (1.0%)”“2 (1.0%)”“1 (0.5%)”
Acute pancreatitis“0”“0”“0”
Cardiac abnormalities suggestive of cardiac fibrosis“0”“0”“0”
Malignancy other than NMSC: prostate cancer“0”“0”“1 (0.5%)”
Malignancy other than NMSC: breast cancer“0”“0”“1 (0.5%)”
Malignancy other than NMSC: colonic dysplasia“0”“0”“1 (0.5%)”
NMSC: basal cell carcinoma“1 (0.5%)”“0”“2 (1.1%)”
NMSC: squamous cell carcinoma“0”“1 (0.5%)”“2 (1.1%)”
Part 2 treatment-emergent adverse events in induction non-responders and Part 1 relapsers
Event, n (%)Obefazimod 25 mg (N=186)Obefazimod 50 mg (N=447)
Any TEAE“132 (71.0%)”“307 (68.7%)”
TEAE leading to study drug discontinuation“21 (11.3%)”“27 (6.0%)”
Serious TEAE“16 (8.6%)”“23 (5.1%)”
Death, not treatment related“1 (0.5%)”“0”
Pregnancy“1 (0.5%)”“1 (0.2%)”
Serious or severe (grade 3 or higher) infections and opportunistic infections“5 (2.7%)”“5 (1.1%)”
Malignancies excluding NMSC“0”“2 (0.4%)”
NMSC“2 (1.1%)”“2 (0.4%)”
Acute pancreatitis“1 (0.5%)”“1 (0.2%)”
Cardiac abnormalities suggestive of cardiac fibrosis“0”“0”
Exposure-adjusted incidence of malignancies excluding NMSC (post-hoc), with the company's expected background range
Analysis setPlacebo, IR/100 PY25 mg, IR/100 PY50 mg, IR/100 PYAll active, IR/100 PYExpected UC background
Integrated UC program (phase 2 and phase 3)“0.00”“0.00”“0.64”“0.35”“0.30 – 0.70”
Phase 3 maintenance (Part 1 and Part 2)“0.00”“0.00”“0.91”“0.56”“0.30 – 0.70”
Part 2 only“-”“0.00”“0.69”“0.48”“0.30 – 0.70”
Exposure-adjusted incidence of non-melanoma skin cancer (post-hoc), with the company's expected background range
Analysis setPlacebo, IR/100 PY25 mg, IR/100 PY50 mg, IR/100 PYAll active, IR/100 PYExpected UC background
Integrated UC program (phase 2 and phase 3)“0.46”“0.53”“0.64”“0.59”“0.70 – 1.40”
Phase 3 maintenance (Part 1 and Part 2)“0.68”“1.09”“1.37”“1.26”“0.70 – 1.40”
Part 2 only“-”“1.52”“0.69”“0.95”“0.70 – 1.40”
Acute pancreatitis and cardiac abnormalities suggestive of cardiac fibrosis: ABTECT maintenance Part 1
EventPlacebo (N=192)Obefazimod 25 mg (N=193)Obefazimod 50 mg (N=195)
Acute pancreatitis“0”“0”“0”
Cardiac abnormalities suggestive of cardiac fibrosis“0”“0”“0”
Study limitations
Summary

As of November 2026, the results of ABTECT Maintenance come only from company press releases of June 1 and June 29, 2026, a prospectus supplement, and two slide presentations at UEG Week 2026. No peer-reviewed publication exists, the ClinicalTrials.gov record shows “No Results Posted”, and the EU register states that the trial has not ended; no protocol or statistical analysis plan for this trial is posted on ClinicalTrials.gov. The long-term extension continues to an estimated study completion in May 2030.

Part 1 is a randomized withdrawal design. Its 580 analyzed participants (192 placebo, 193 obefazimod 25 mg, 195 obefazimod 50 mg) had all responded to 8 weeks of obefazimod induction, so the placebo group measures withdrawal of obefazimod after an initial response; participants without an induction response are reported separately in Part 2. Of the 678 induction responders who entered Part 1, placebo induction responders were kept on blinded placebo and are outside the 580-participant comparison. Completion of Week 44 without relapse or treatment switch was 66 of 192 (34.3%) with placebo, against 152 of 193 (78.8%) and 160 of 195 (82.1%) with obefazimod 25 mg and 50 mg, so most placebo participants left the randomized treatment before Week 44; the handling of these participants in the efficacy analysis has not been published.

The timepoint is reported as Week 44 in the press releases and registry and as “Week 52” in the UEG Week slides, which count the 8-week induction. The registries differ: ClinicalTrials.gov names clinical remission at Week 44 as the Part 1 primary endpoint, while the EU register states the Part 1 objective as comparing obefazimod with placebo on “endoscopic improvement and symptomatic remission” and lists clinical remission at Week 44 among the Part 1 endpoints. Symptomatic remission (66.8% and 65.6% with obefazimod against 22.9% with placebo) is reported only in the slides, and its printed definition reads “RBS=0, SFS <1”. Corticosteroid-free clinical remission is registered in the subpopulation receiving corticosteroids at maintenance entry, while the reported counts (19 of 192, 87 of 193, and 93 of 195) use all randomized participants as the denominator.

Prior advanced therapy failure was more frequent in the 50 mg group (46.2%) than in the 25 mg (39.4%) and placebo (37.5%) groups. Placebo-adjusted differences were numerically smaller in participants with prior inadequate response to advanced therapy (clinical remission differences of 28% and 33%) than in those without (48% and 45%). The subgroup analyses by number of prior advanced therapies and after JAK inhibitor failure involved 9 to 41 participants per group, and their differences are unadjusted with nominal p-values that the presenters describe as “descriptive rather than confirmatory”; the sustained clinical remission subgroup with prior advanced therapy failure included 13, 15, and 23 participants.

Part 2 efficacy results come from groups without a placebo comparator: induction non-responders who continued obefazimod (81 on 25 mg and 148 on 50 mg) and Part 1 relapsers re-treated with open-label 50 mg (109 previously on placebo and 33 previously on 25 mg). The company labels these results exploratory and the integrated safety analyses post-hoc.

Malignancy findings rest on small numbers of events. In Part 1, the 50 mg group had one prostate cancer, one breast cancer, and one colonic dysplasia, listed by the release under malignancies other than NMSC, and four NMSC (two basal cell and two squamous cell carcinomas), against one NMSC with placebo and one with 25 mg; no malignancy other than NMSC occurred with placebo or 25 mg. Part 2 added two malignancies excluding NMSC (a myeloproliferative neoplasm and a prostate cancer, both in Part 1 placebo relapsers re-treated with 50 mg) and four NMSC, two of which the investigators judged probably related to study drug. In the phase 3 maintenance dataset, the exposure-adjusted incidence of NMSC was 1.37 per 100 patient-years with 50 mg and 0.68 with placebo, and of malignancies excluding NMSC 0.91 with 50 mg and 0.00 with placebo. The company's comparison of these rates with a “UC background reference range” is post-hoc and compares the trial's rates with an external reference range from published studies. Part 2 also reported one death from suspected pulmonary embolism, assessed as unrelated, and one case of acute pancreatitis in each dose group, an event with no cases in Part 1.